Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke | Zendy

Subodh Verma | Zendy; Neil R Poulter | Zendy; Deepak L. Bhatt | Zendy; Stephen C. Bain | Zendy; John B. Buse | Zendy; Lawrence A. Leiter | Zendy; Michael A. Nauck | Zendy; Richard E. Pratley | Zendy; Bernard Zinman | Zendy; David D. Ørsted | Zendy; Tea Monk Fries | Zendy; Søren Rasmussen | Zendy; Steven P. Marso | Zendy

Open Access

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke

Author(s) -

Subodh Verma,

Neil R Poulter,

Deepak L. Bhatt,

Stephen C. Bain,

John B. Buse,

Lawrence A. Leiter,

Michael A. Nauck,

Richard E. Pratley,

Bernard Zinman,

David D. Ørsted,

Tea Monk Fries,

Søren Rasmussen,

Steven P. Marso

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.034516

Subject(s) - medicine , liraglutide , stroke (engine) , myocardial infarction , diabetes mellitus , cardiology , type 2 diabetes , incidence (geometry) , adverse effect , surgery , endocrinology , mechanical engineering , physics , optics , engineering

The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes). In a post hoc analysis, we evaluated the efficacy of liraglutide in those with and without a history of myocardial infarction (MI) and/or stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research